Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05871606 · ClinicalTrials.gov registry record · Phase 1

Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy

A Phase 1 study of Cerebrovascular Disorders and Acute Cerebrovascular Disease, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
Phase 1
Development phase
36
Enrollment target
2
Study locations

NCT05871606 is a Phase 1 study of Cerebrovascular Disorders and Acute Cerebrovascular Disease that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 36 participants, below the 1,092-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05871606, a Phase 1 study of Cerebrovascular Disorders and Acute Cerebrovascular Disease, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).

Interventions

  • DRUG iNO

Study Locations (2)

North Carolina

  • Carolinas Medical Center - Charlotte
  • Atrium Health - Charlotte

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-11-11
Est. Completion 2028-12
Phase Phase 1

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT05871606

The ClinicalTrials.gov registry entry for NCT05871606 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,092-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cerebrovascular Disorders appearing as the primary indexed condition, and to 1 intervention - of which iNO is the first listed.

NCT05871606 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05871606 about?

NCT05871606 is a clinical study titled "Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy". The purpose of this study is to determine the safety and feasibility of using inhaled nitric oxide (iNO) in patients undergoing intra-arterial mechanical thrombectomy (blood clot extraction or IAMT) for treatment of acute ischemic (non-bleeding) stroke (AIS).

What is the current status of trial NCT05871606?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-11-11. Estimated completion is 2028-12.

What conditions does trial NCT05871606 study?

This clinical trial studies the following conditions: Cerebrovascular Disorders, Acute Cerebrovascular Disease.

What interventions are being tested in trial NCT05871606?

The interventions under investigation include: iNO (DRUG).

Who is sponsoring clinical trial NCT05871606?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05871606 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebrovascular Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.